Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: Clinuvel Pharmaceuticals Limited

Market Cap 519M 365M 318M 293M 276M 516M 34.39B 3.49B 1.35B 16.95B 1.37B 1.34B 58.75B P/E 2026 *
13.9x
P/E 2027 * 13.1x
Enterprise Value 266M 187M 163M 150M 141M 264M 17.59B 1.78B 693M 8.67B 701M 686M 30.05B EV / Sales 2026 *
2.67x
EV / Sales 2027 * 2.22x
Free-Float
83.79%
Yield 2026 *
0.62%
Yield 2027 * 0.81%
Manager TitleAgeSince
Chief Executive Officer 63 31/10/2005
Director of Finance/CFO 42 29/06/2024
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member - 28/01/2018
Director/Board Member - 22/09/2019
Chairman - 31/12/2023
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00% - - 352M
+0.33%-0.25%+18.76%-22.11% 62.05B
-0.80%-10.08%+56.80%+193.59% 54.45B
+4.38%+43.00%+43.00%+43.00% 43.09B
+7.62%+8.19%-51.27%-59.11% 36.37B
+0.79%-1.69%+55.35%-33.92% 29.02B
+0.56%+28.85%+151.81%-50.31% 25.38B
-0.10%-8.91%+43.87%+55.34% 19.62B
+1.74%+4.39%-3.12%+107.49% 16.89B
-0.05%+0.41%+56.32%+94.95% 15.93B
Average +1.49%+3.20%+41.28%+36.55% 33.64B
Weighted average by Cap. +1.70%+2.21%+37.68%+36.41%

Financials

2026 *2027 *
Net sales 99.46M 69.88M 60.88M 56.13M 52.79M 98.76M 6.59B 668M 259M 3.25B 262M 257M 11.25B 105M 74.02M 64.5M 59.45M 55.92M 105M 6.98B 707M 275M 3.44B 278M 272M 11.92B
Net income 35.97M 25.27M 22.02M 20.3M 19.09M 35.72M 2.38B 241M 93.78M 1.17B 94.85M 92.82M 4.07B 38.2M 26.84M 23.38M 21.56M 20.28M 37.93M 2.53B 256M 99.6M 1.25B 101M 98.58M 4.32B
Net Debt -254M -178M -155M -143M -135M -252M -16.8B -1.7B -661M -8.28B -669M -655M -28.69B -286M -201M -175M -161M -152M -284M -18.94B -1.92B -746M -9.33B -754M -738M -32.35B
Logo Clinuvel Pharmaceuticals Limited
Clinuvel Pharmaceuticals Limited is a specialty pharmaceutical company. It is focused on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening, acute disorders, as well as healthcare solutions for specialized populations. Its lead therapy, SCENESSE (afamelanotide 16mg), is approved for commercial distribution in Europe, the United States of America, Israel, and Australia as the first systemic photoprotective drug for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). It has operations in Europe, Singapore, and the United States of America. It develops and manufactures NEURACTHEL (adrenocorticotropic hormone) in different formulations, to target neurological, endocrinological, and degenerative disorders. Its pharmaceutical product, PRENUMBRA, has been developed, and its use is to be expanded in the clinic from stroke to Parkinson's.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
CCC
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!